Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZachary J. WalkerMKM. Eric Kohler

Discussion

Loading...

Member takes

Overview

Findings reveal that frontline induction therapy reduces CAR-T cell cytotoxicity in multiple myeloma, suggesting the need for earlier T cell collection.

Key Points

  • Post-induction CAR-T cells showed a significant reduction in cytotoxicity against tumor cells compared to newly diagnosed cells.
  • Manufacturing efficiency of CAR-T cells decreased significantly after frontline therapy, with a notable reduction in CD4/CD8 ratios.
  • The study identified increased levels of the inhibitory receptor TIGIT and decreased naïve T cells in post-induction CAR-T products.
  • Results suggest that early collection of T cells could enhance the effectiveness of CAR-T therapy in multiple myeloma patients.

Cite This Study

Walker et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d6https://doi.org/10.1182/blood-2025-5725
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis2025 · 1 citations
  2. 2Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025
  3. 3The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  4. 4Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM2025
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025